OXFORD
UNIVERSITY PRESS

Human Reproduction Open

EARLY-PREG protocol: Preconception, longitudinal, bidirectional, and counterfactual cohort of women trying to conceive for maternal–embryonic molecular crosstalk characterisation during the first weeks after conception.

Journal:	*Human Reproduction Open*
Manuscript ID	HROPEN-25-0666
Manuscript Type:	Protocol
Date Submitted by the Author:	19-Nov-2025
Complete List of Authors:	Koch, Elard; MELISA Institute, Department of Epidemiology Ávila, Denisse; MELISA Institute, Department of Clinical Protocols Nourdin-Galindo, Guillermo; MELISA Institute, Department of Bioinformatics Latapiat, Verónica; MELISA Institute, Department of Bioinformatics Antilef, Bárbara; MELISA Institute, Department of Biotechnology Contreras, Estefanía; MELISA Institute, Department of Biotechnology Hernández, Mauricio; MELISA Institute, Department of Biotechnology Stecher, Juan; MELISA Institute, Department of Clinical Protocols Vargas, Cristian; MELISA Institute, Department of Biotechnology
Keywords:	Preconception open cohort, Longitudinal study, Counterfactual design, Ultra-early pregnancy, Embryo-mother crosstalk, Biorepository, Maternal fluids, Menstrual cycle

SCHOLARONE™
Manuscripts

1   **EARLY-PREG protocol:** Preconception, longitudinal, bidirectional, and counterfactual
2   cohort of women trying to conceive for maternal–embryonic molecular crosstalk
3   characterisation during the first weeks after conception.
4
5   **Running Title:**
6   Early pregnancy preconception cohort protocol.
7

8   Elard S. Koch [1]*, Denisse Avila[1]; Guillermo Nourdin[1]; Veronica Latapiat[1]; Barbara Antilef[1];
9   Estefanía Contreras[1]; Mauricio Hernandez [1]; Juan F. Stecher [1]; Cristian Vargas[1].
10
11 Author affiliations
12 (1) MELISA Institute, Dalcahue 1120, San Pedro de la Paz, 4133515, Concepcion, Chile.
13 (*) Corresponding author: Elard S. Koch (ekoch@melisainstitute.org, +56-968789130).

14
15 **ABSTRACT**
16

STUDY QUESTIONS
Embryo–maternal crosstalk involves intense and complex molecular exchange between the early
embryo and the mother. This interaction begins after fertilisation but is poorly understood before
implantation. EARLY-PREG is a preconception open cohort that aims to research the proteome
signature of maternal–embryonic communication, interrogating a growing biorepository of
maternal fluids and tissues collected during the first two weeks of a natural conception.
23

WHAT IS KNOWN ALREADY
To understand the mother-embryo communication in humans, *in vivo*, *ex vivo*, and *in vitro*
biological models have been developed to simulate certain phases of the implantation process
and its related events. Mass Spectrometry (MS) for proteomic profiling in longitudinal cohort
studies has emerged as a modern method for understanding complex biological processes
directly *in vivo*. Proteomic profiles have been investigated during pregnancy in women from the
8th week of gestation, but not before.
31

STUDY DESIGN, SIZE, DURATION
In three waves of recruitment from 2017 to 2024 so far, healthy women seeking to conceive have
been recruited in Concepcion, Chile. Participants completed a survey with health, lifestyle, and
sociodemographic data, their menstrual cycles with ovulation, and fertile window ascertainment
(ultrasound, fertility monitor, and/or LH strips) were followed prospectively until pregnancy was
achieved, or for a maximum of six consecutive cycles. The follow-up of every cycle included
systematic day-by-day sampling of cervicovaginal fluid (CVF), urine, saliva, and blood. In addition,
we collected a cervical brushing between days 12th and 14th post-ovulation. The day of ovulation
and other time windows of interest in each cycle were retrospectively corrected by hormonal
curves (LH, oestradiol, progesterone and beta-hCG) on stored blood and urine samples. Cervical
brushings were collected on day 21 post-ovulation and in each trimester of pregnancy.

PARTICIPANTS, MATERIALS, SETTING, METHODS
At present, 1,183 women have been contacted, of whom 223 met all eligibility requirements; 129 participants who were trying to conceive completed the protocol for at least one complete cycle, of whom 35 participants achieved full-term pregnancies and 17 had early pregnancy losses; 40 abstinent and 5 sterilised women entered and completed the protocol. A total of 293 menstrual cycles have been fully documented and sampled; 53 have been classified as conception cycles and 240 as non-conception cycles; of the latter, 31 correspond to non-conception counterfactual cycles and 209 to non-counterfactual cycles. The biorepository encompasses maternal fluids and tissues collected throughout the first 2 weeks after ovulation for all 293 cycles to date. Biospecimen collection compliance has been high for most specimens. The cohort is currently supporting proteomic analyses of maternal fluids from women who conceived and their counterfactual non-conception cycles to characterise the proteome signature of early pregnancy. A fourth recruitment wave to characterise changes of the immunophenotype in maternal peripheral blood mononuclear cells (PBMC) during ultra-early pregnancy is planned to begin in 2025.

STUDY FUNDING/COMPETING INTEREST
The EARLY-PREG preconception open cohort has been supported by multiple research grants awarded by the FISAR Foundation (www.fisarchile.org). The pilot study and the first wave of recruitment were supported by grants #MEL109112011 and #MEL109112011R4 awarded to E.S.K., C.V. and J.F.S. The second wave of recruitment was supported by supplemental grants #MEL109112011R5 and #MEL131032017R1 awarded to E.S.K. The third wave was supported by grant #MEL205062018 awarded to E.S.K. and M.H. Current funding for the design of the fourth recruitment wave and MS research on maternal CVF is supported by grant No. REH042024-01 awarded to M.H., G.N., and E.S.K. As a senior scientist, E.S.K. has served as an honorary research consultant and/or reviewer on research applications for the FISAR Foundation since 2015. No other conflicts of interest are reported.

TRIAL REGISTRATION NUMBER
Not applicable.

TRIAL REGISTRATION DATE
Not applicable.

DATE OF FIRST PATIENT'S ENROLMENT
Not applicable.

KEYWORDS
Preconception open cohort, longitudinal study, counterfactual design, ultra-early pregnancy, embryo-mother crosstalk, biorepository, maternal fluids, menstrual cycle.

Introduction

Embryo–maternal crosstalk is critical for the establishment of a successful pregnancy. The period after fertilisation and before implantation, known as the *preimplantation* period, was previously thought to be silent. However, evidence suggests that this communication lays the groundwork for pregnancy (Barnea *et al.*, 2012). During this period, intense and complex molecular exchange occurs between the early embryo and the maternal endometrium (Lane *et al.*, 2014). At present, researchers have not fully characterised this interaction (Lynch *et al.*, 2006; Benagiano *et al.*, 2023a, 2023b). This embryo–mother dialogue involves a complex interaction between the embryo and the mother, starting at fertilisation, termed the ultra-early stages of pregnancy (Hill, 2001; Barnea, 2004; Singh *et al.*, 2011). Through this communication, the embryo can modulate the maternal response during key phases, such as apposition, adhesion, invasion, and decidualisation in the endometrium, through extensive exchange of signals (Somerset *et al.*, 2004; Barnea, 2007; Lédée *et al.*, 2007; Fazeli, 2011). The success of each of these events is essential for advancing to the next stage. However, the regulatory mechanisms that govern this embryo–mother interaction are still not completely understood (Cha *et al.*, 2012).

During the preimplantation period, the uterine fluid potentially facilitates the transfer of vital information between mother and embryo (Zhang *et al.*, 2017). In this context, the presence of molecules involved in the interaction between the embryo and the maternal environment, such as the early pregnancy factor (EPF, Morton *et al.*, 1982), preimplantation factor (PIF) (Barnea *et al.*, 1994) and PAF (embryo-derived platelet-activating factor), has been reported (O'Neill, 1992, 2005). EPF and PIF are involved in the maternal immune response, which is crucial for the viability of early embryos and implantation (Nahhas and Barnea, 1990; Morton, 1998; Barnea *et al.*, 2012, 2014; Santos *et al.*, 2021). It has been postulated that EPF originates from the mother during the preimplantation period and shifts to embryonic origin after implantation (Nahhas and Barnea, 1990; Morton, 1998; Barnea *et al.*, 2012, 2014; Santos *et al.*, 2021). PIF secreted by the embryo has recently been suggested to enhance the decidualisation process and the production of endometrial factors that limit trophoblastic invasion (Santos *et al.*, 2021). Moreover, a third factor known as PAF has been described; its activity as an embryotrophin would mediate the transport of the embryo to the uterus (O'Neill, 1992, 2005). In addition, recent studies have shed light on new forms of embryo–maternal communication via the delivery and/or exchange of extracellular vesicles (EVs) and mobile RNAs. Furthermore, EVs play a role in generating an immunosuppressed environment during embryo–mother interactions (Simon *et al.*, 2018; Kaminski *et al.*, 2019; Das and Kale, 2020), allowing the embryo to counteract the maternal immune response (Burnett and Nowak, 2016). Nevertheless, further investigation is needed to fully understand the embryo–mother dialogue.

Embryo–mother communication in humans is a unique and challenging-to-model process. Commonly, *in vivo*, *ex vivo*, and *in vitro* models have been developed to simulate certain phases of the implantation process and its related events (Dimova *et al.*, 2024). Despite advances in experimental strategies, understanding the mechanisms of embryo–maternal crosstalk faces inherent limitations that affect how well its findings can be extrapolated to humans. Notably, variation between humans and animal models has been observed in decidualisation, the timing

and type of implantation, attachment, trophoblast subpopulations, and the depth of extravillous
trophoblast invasion (Muter *et al.*, 2023; Dimova *et al.*, 2024). Moreover, *in vitro* models designed
to replicate the implantation process have been developed using immortalised cell lines or cancer
cells, which may not accurately represent normal physiological conditions (Shibata *et al.*, 2024).
Thus, the maternal–embryonic dialogue during early stages requires further research using novel
strategies tailored to human physiology.

In recent years, proteomic profiling in longitudinal cohort studies has emerged as a modern
strategy for understanding complex biological processes (Romero *et al.*, 2017; Aghaeepour *et al.*,
2018; Yohannes *et al.*, 2022). These advancements have been driven by innovations in Mass
Spectrometry (MS), which have allowed the integration of proteomic data with pathway analysis.
Proteomics has proven to be a reliable and highly sensitive method for biological research (Cox
and Mann, 2011; Geyer *et al.*, 2017), particularly because of its ability to analyse biological fluids
(Bader *et al.*, 2023). Proteomic profiling, combined with longitudinal sampling of biological fluids,
is a non-invasive alternative to monitoring processes, such as the embryo–mother molecular
exchange of signals.

Longitudinal proteomic profiles during pregnancy in healthy women have been investigated in a
few cohort studies, starting from the 8th week of gestation. Although these studies have
performed proteomic analyses during pregnancy, to date, no studies have characterised the first
two weeks of gestation from the time of conception (Romero *et al.*, 2017; Hedman *et al.*, 2020).
Consequently, the earliest stages of maternal–embryonic interaction remain poorly understood,
particularly without altering, manipulating, or intervening in their natural environment.

To address this gap, we designed EARLY-PREG, a preconception, longitudinal, bidirectional, and
counterfactual cohort study. EARLY-PREG investigates maternal–embryonic communication
during the first two weeks after conception through a biorepository of maternal biological fluids
and tissues collected frequently throughout the preimplantation period and into pregnancy.
Crucially, the value of this cohort depends on the implementation of advanced analytical
strategies that can sensitively and reproducibly capture the molecular complexity of
cervicovaginal fluid (CVF), a biofluid central to reproductive physiology (Zegels *et al.,* 2010;
Fernandez-Hermida et al., 2018). In a companion study, we validated a data-independent
acquisition parallel accumulation–serial fragmentation (dia-PASEF) method for CVF large scale
longitudinal proteomics with repeated measures over time identifying specific physiological
windows, demonstrating superior reproducibility, reduced missing values, and improved
quantification of low-abundance proteins compared with traditional approaches (Hernandez *et al.,*
2025). Incorporating this methodology into EARLY-PREG ensures that the unique temporal
resolution of the cohort can be fully leveraged to discover dynamic proteomic signatures of early
pregnancy.

This protocol article completely outlines the study design and provides an overview of the data
collected so far, including baseline participant information, reproductive outcomes, menstrual
cycle characteristics, biological samples, and protocol performance.

Cohort description

Study design

The preconception study employs an open longitudinal, bidirectional, and counterfactual cohort design, which is prospective when successive day-by-day samples are collected and retrospective for analysis once pregnancy is confirmed. In addition, this design allows each participant to serve as their own control (counterfactual), enabling the comparison of non-conception and conception cycles while minimising interindividual variability, as detailed in Figure 1.

Bidirectional longitudinal design

Given the study's objective, a longitudinal prospective follow-up with repeated measures was established, beginning before the onset of pregnancy in the study participants. Measurements were planned to continue while couples sought pregnancy throughout the menstrual cycles, during pregnancy, and until delivery. A bidirectional or two-way component was incorporated into longitudinal follow-up for sampling. Consequently, the occurrence of pregnancy serves as a milestone for the retrospective hormonal analysis (LH, oestradiol, progesterone and beta-hCG) of the stored samples to correct and synchronise specific time periods of interest, such as the fertile window, the preimplantation window, and the implantation window.

Counterfactual approach

Counterfactual models use hypothetical scenarios to estimate the outcomes that individuals would have experienced if they had been exposed to a different intervention than the one they received. The counterfactual design of EARLY-PREG enables a comparison of the systemic and localised effects of embryo appearance and implantation in an individual (the factual) against the physiological state of the same individual without experiencing pregnancy (the counterfactual). Comparison of an early-in-life event with a late-in-life event was restricted to a range of up to six menstrual cycles from the start of active pregnancy seeking (Eichler *et al.*, 2016).

Setting and recruitment

The EARLY-PREG cohort consists of healthy couples trying to conceive and women not trying to conceive. Since 2017, a total of 1,183 women have been invited to participate through word of mouth, invitations from gynaecologists, and midwives in private practices, public hospitals, and Family Health Centres (CESFAMs) in the Biobio region of Chile.

Women interested in participating in the study went through a pre-selection phase to receive general information about the study in a consultation room at the *Sanatorio Aleman* Clinic in Concepcion, Chile. Potential participants were subsequently interviewed by the midwife to address any questions from the recruitment team and to request participation in the study from

216   the women and their partners (in the case of couples trying to conceive), which was formalised
217   through corresponding informed consent.
218
219   **Selection Criteria**
220
Eligibility requirements common to all women include being between 18 and 40 years of age, not
being pregnant, normal colposcopy, body mass index (BMI) between 18 and 29, having regular
menstrual cycles (21–35 days), and absence of chronic diseases (hypertension, diabetes mellitus,
cancer, depression, personality disorder, thyroid pathology, polycystic ovary syndrome, or
hyperprolactinemia). Pregnant women and those with a history of alcoholism, infertility treatment,
endometriosis, pelvic inflammatory disease or pelvic surgery, or allergy to latex or silicone were
excluded. In addition, eligibility criteria were established for the partners of women trying to
conceive. Women were included if their partners were males between 18 and 40 years old, without
pathologies (diabetes mellitus, depression, personality disorder, or cancer), were not taking
chronic medication, without erectile disorders, BMI between 18 and 29.9, moderate alcohol use,
and with no recreational drug use. The exclusion criteria were working in contact with pesticides,
a history of erectile dysfunction, mumps in adulthood, chronic diseases, and psychological
problems.
234
235   **Study groups**
236
Figure 2 shows the recruitment flowchart for the entire EARLY-PREG cohort. The women enrolled
so far in the study are divided into two main categories: women trying to conceive (TCG) and
women who are not seeking pregnancy, which represents a negative control group (NCG). The
negative control group is further categorised into two subgroups: women practising abstinence
and women who were sterilised. Within the sterilised women, there are additional subdivisions:
women with sexual abstinence and women without sexual abstinence. These negative control
groups will be used to establish proteome libraries under initial conditions that differ from those of
conception or the ultra-early pregnancy stage.
245
246   Throughout the study, participants are monitored during their cycles through the collection of
247   various biological samples, including blood, urine, saliva, CVF, and cervical brushing, for both
248   groups. The NCG is followed for a single complete cycle, whereas the TCG is monitored over
249   multiple cycles (up to six cycles), with serial collection of biological samples. If a pregnancy is
250   identified in the TCG study group, monitoring continues until the pregnancy concludes.
251
A total of 1,183 women have been contacted so far and were recruited during the screening
phase. A total of 223 participants were selected and agreed to participate in the study through
consent forms and enrolment in the protocol. During the study, 49 participants withdrew from the
protocol (21.97%) (Figure 2). The main reasons for withdrawal were classified as personal or
medical. A total of 292 menstrual cycles from 174 women have been monitored so far, with 35
achieving full-term pregnancies.
258
259   **Patient and public involvement**

260
261   The study participants were not involved in the design, conduct, reporting, or dissemination of our
262   research. They were not directly involved in the study's design, the development of the research
263   questions and outcome measures, or the recruitment and execution.
264
265   The protocol was reviewed and approved by the ethics committee of the Servicio de Salud
266   Concepcion, Biobio region, Chile (CODE: 17-03-06). The committee's role was to advise on the
267   ethical and operational aspects of the study.
268
269   **Questionnaire survey**
270
At enrolment, both female and male participants complete a baseline questionnaire survey, which
is conducted and recorded by a midwife from the research team. The questionnaire includes
sections for females, males, and sociodemographic information. Both women and their male
partners (when applicable) are asked about their health (e.g., BMI, allergies, chronic diseases,
and use of chronic medications) and lifestyle (e.g., smoking habits, alcohol consumption, drug
use, habit of coffee drinking, and physical activities). Additionally, women are asked about
contraceptive use, reproductive and general obstetric history, and dietary habits. The
sociodemographic section includes questions on marital status, age, educational level,
occupation, and income.
280
281   **Methods**
282
283   **Main Outcomes**
284
285   The three main outcomes in the cohort are menstrual cycles in which conception is achieved and
286   menstrual cycles in which conception is not achieved. Below are their respective clinical
287   definitions:
288
289   ● **Conception cycle** refers to the cycle in which the ovum is fertilised, leading to pregnancy.
290   The conception cycle requires beta-hCG levels above the clinical threshold for a positive
291   pregnancy test, which is determined in peripheral venous blood on the 14th day post-
292   ovulation.
293
294   ● **Non-conception cycle** refers to a menstrual cycle in which pregnancy does not occur.
295   When referring to the same individual, it is, by definition, considered the counterfactual to
296   the conception cycle described above. The non-conception cycle requires a clinically
297   negative beta-hCG test, which is determined in peripheral venous blood on the 14th day
298   post-ovulation. This cycle is characterised by the absence of a clinical pregnancy.
299
300   ○ **Negative control cycle** refers to cycles in which conception did not occur because
301   of abstinence and/or sterilisation.
302
303   **Recruitment, biospecimen collection and follow-up**

304
305   **Recruitment phase**
306
307   Approval by the ethics committee of the Servicio de Salud de Concepcion was obtained before
308   the recruitment stage. Participants were recruited through medical consultations, health centres,
309   and referrals from doctors and midwives. An initial interview was conducted to explain the details
310   of the study and assess eligibility based on the inclusion and exclusion criteria. The study was
311   discussed in a private room at the respective health centres, and informed consent was obtained.
312
313   Each participant undergoes a clinical evaluation, including a physical examination and
314   speculoscopy. A Papanicolaou (Pap) test was administered to women who had not recently
315   undergone one to screen for cervical cancer. Instructions for cycle follow-up were provided both
316   orally and in writing.
317
318   **Data collection**
319
320   Personal, clinical, and follow-up data have been collected in individual files. Each participant is
321   anonymised and assigned a unique code to ensure data confidentiality.
322
323   Additionally, the midwives responsible for recruitment and follow-up transfer the information from
324   the physical records to a digital document on password-protected computers belonging to
325   MELISA Institute.
326
327   The collected samples are registered in a digital inventory stored on password-protected
328   computers belonging to MELISA Institute. Each sample is registered using the unique code
329   assigned to each participant to ensure confidentiality.
330
331   **Ovulation and fertile window ascertainment**
332
Although conception cannot be directly observed, estimating the day of ovulation allows
researchers to narrow the time frame during which fertilisation is most likely to occur (Wilcox *et*
al., 1995). Furthermore, the estimation of ovulation day allows the targeted collection of biological
samples to characterise and investigate the fertile window in non-conception cycles and the
periimplantation window in conception cycles. The EARLY-PREG cohort has undergone three
recruitment waves so far, each defined by variations in the clinical method used to estimate the
day of ovulation and fertile window, following the proposed schema in Figure 3A. The pilot study
and first wave relied on ultrasound to determine ovulation. The second wave employed a portable
fertility monitor (Clearblue Digital Ovulation test). In the third wave, commercial LH strips were
used to infer ovulation from urine samples. All recruitment waves included a professional
instructor who taught women how to estimate their fertile window with the Billings method.
Detailed, hand-filled fertility charts were used for each cycle. A nurse or midwife in daily contact
with each couple provided reproductive counselling.
346
347   **Correction and synchronisation of counterfactual cycles**

348
Given the high variability of menstrual cycles, identifying the day of ovulation is a key issue in the
EARLY-PREG cohort. In fact, this day, estimated with a precision margin of approximately 12
hours, is considered the most reliable proxy for the day of conception, or day 0, in the cohort of
pregnant women. The two-way or bidirectional design used in the present preconception cohort
offers a critical temporal framework for studying ultra-early pregnancy events with improved
accuracy for multiple non-conception and conception menstrual cycles in a single individual
following a counterfactual model. The fertile window typically includes the five days preceding
ovulation, the day of ovulation itself, and the day following the estimated ovulation (Wilcox *et al.*,
1995). While all the above methods offer a pragmatic approach to clinically estimating the fertile
window and providing reproductive counselling at the specific period of the menstrual cycle during
which conception is possible, these methods, however, are inaccurate and do not allow
synchronisation of multiple cycles for research purposes.Therefore, to address this major issue,
comprehensive laboratory analyses of hormone curves—including LH and beta-hCG in urine, and
oestradiol and progesterone in serum—are retrospectively conducted on stored samples to more
accurately synchronise the day of ovulation across multiple counterfactual cycles and/or to identify
the preimplantation window within a conception cycle more precisely. An example of a multi-cycle
correction method used to synchronise ovulation (LH-based approach) and implantation (beta-
hCG-based approach) used in the cohort is presented in Figure 4. The combination of these
methods allows for a more precise isolation of specific time windows of interest in counterfactual
cycles within the same individual.

Biological material handling and storage
The strategy for collecting biological samples used in the EARLY-PREG cohort is intensive and
challenging. The protocol is based on daily serial collection of CVF, urine, saliva and blood. A
cervical brushing sample is collected between days 12 and 14 post-ovulation in all participants.
Additionally, blood samples and cervical brushings are collected from pregnant women on day 21
after ovulation and at each trimester of pregnancy. Finally, placenta and umbilical blood are
obtained at childbirth (Figure 3B). Serial sampling has been performed during the phases of
interest, including the follicular, periovulatory, and luteal phases. The specific details about the
collection protocols for each sample are described below:
378
Blood
Four tubes of venous blood are drawn using BD Vacutainer tubes: two with EDTA
(ethylenediaminetetraacetic acid) for proteomic analysis, peripheral blood mononuclear cell
extraction, and platelet count, and two with a separator gel and coagulation activator for beta-
hCG and hormone analysis. The samples are collected by nursing staff and transported to the
laboratory in a cooler box with cold gel packs. The plasma is obtained by centrifugation at 2000
× g for 15 minutes and stored at -80 °C.
386
Urine
The participants are trained to collect morning urine at home in a sterile 60 mL container,
discarding the initial stream. Instructions are given to keep the samples refrigerated (~4 °C) until
daily collection. The urine samples were transported to the laboratory in a cooler box with cold
gel packs. In the laboratory, the samples were centrifuged (600 × g, 10 minutes), and the
supernatants were stored at -80 ºC for hormone analysis (oestradiol, FSH, LH, progesterone, and
beta-hCG).
394
Saliva
The participants collect ~1 mL of saliva at home using Salimetrics SalivaBio passive collectors
before eating and after brushing their teeth in the mornings. Instructions from the manufacturer
are provided to participants for the collection of samples. Saliva samples are collected daily and
transported to the laboratory in a cooler box with cold gel packs. The samples are stored directly
at -80 °C in cryotubes.
401
Cervicovaginal Fluid (CVF)
The participants collected CVF using a silicone menstrual cup worn for two hours during the first
hours of the morning. Cups are washed with a pipette using a buffer that contains PBS,
physiological serum, and protease inhibitors and then transferred into a borosilicate tube. The
samples are retrieved daily and transported to the laboratory in a cooler box with cold gel packs.
These samples are subsequently processed (centrifuged and aliquoted) and then stored at -80
°C.
409
Cervical Brushing
Cervical brushing samples are collected from the cervical canal area by trained staff via a Rovers
Cervex-Brush. The brush is then placed in a 50 mL tube containing medium enriched for

trophoblastic cells (RPMI) with foetal bovine serum (FBS) and antibiotics. The samples are
transported to the laboratory within 4 hours of collection via a cooler box with cold gel packs.
Brushes are washed with PBS and then centrifuged. The collected pellet is resuspended in 400
μL of PBS and transferred to a microcentrifuge tube. Subsequently, 100 μL of 4%
paraformaldehyde is added, and the sample is finally stored at 4 °C for further analysis.
418
Umbilical cord blood
At birth, the obstetrician collected blood from the cord, umbilical vein, and umbilical artery using
BD Vacutainer tubes with EDTA. The sample collection times are recorded, and the samples are
then immediately sent to the laboratory. The umbilical cord blood is transported at room
temperature (20 ºC–25 ºC) in a transport box. Sample processing involved centrifugation to
separate peripheral blood mononuclear cells using Ficoll gradients. The cells are stored in RPMI
medium supplemented with 20% FBS and 5% DMSO. Initially, the samples were stored for two
weeks at -80 °C and then transferred to liquid nitrogen for long-term storage.
427
428 ***Placenta***
429 Obstetricians collected placenta samples at the time of birth. The tissue was sectioned under
430 sterile conditions, placed in a sterile container, and then transported to the laboratory in a cooler
431 box with cold gel packs. The samples were preserved in RPMI medium supplemented with 20%
432 FBS and stored at -80 °C for further analysis.
433
434 **Follow-up stage**
435
436 The length of follow-up is variable between individuals and study groups. The TCG is monitored
437 for up to six menstrual cycles or until pregnancy, whichever comes first. In the case of pregnancy,
438 follow-up is extended to the end of the pregnancy. The NCG is followed for a single menstrual
439 cycle.
440
For all the participants, the follow-up phase begins on the first day of menstrual bleeding after
enrolment, which is reported by the participant to the team via a phone call. This day marks the
establishment of the cycle start date and serves as a milestone for scheduling visits and daily
phone calls with participants. The first visit takes place between the third and fifth days of the
cycle, when trained staff collect urine and peripheral blood samples to exclude pregnancy through
a beta-hCG test. An ultrasound is performed during this visit for gynaecological evaluation of
uterine and ovarian structures (this assessment is performed once). Additionally, the clinical staff
provides counselling to couples regarding sexual intercourse during the fertile window of each
menstrual cycle.
450
For monitoring, days 6 and 9 of the cycle include visits for collecting peripheral blood samples,
CVF, urine, and saliva. After day 9 of the cycle, daily collection of urine, CVF, and saliva continues
until the end of the menstrual cycle. In accordance with one of the ovulation assessment methods,
post-ovulatory monitoring is scheduled. After this estimated point, alternate-day blood sampling
is performed until 10 days post-ovulation. Fourteen days post-ovulation, a visit is scheduled that

includes blood sampling for beta-hCG hormone measurement and cervical brushing. At this
stage, the participants in the NCG conclude their study participation.
458
The TCG repeats the same follow-up protocol above for up to six cycles. Throughout these cycles,
clinical pregnancies are assessed via beta-hCG levels, with clinical pregnancy monitoring
commencing upon detection and continuing until childbirth. Once beta-hCG has been detected,
the participant moves on to the pregnancy monitoring phase. One cervical brushing is performed
on day 21 post-ovulation. Following this, the participants underwent an ultrasound at 7, 11–14,
24–26, and 32–34 weeks. In addition to ultrasound monitoring, blood samples and brushings are
collected during each trimester, specifically at weeks 11–14, 24, and 36. Standard prenatal care,
in accordance with Chilean guidelines, is provided either by the obstetrician from the research
team or by the obstetrician chosen by the participant based on their preference (Minsal, 2015). At
childbirth, placental tissue, umbilical cord blood, and newborn data are collected.
469
470   **Recruitment numbers to date**
471
472   The EARLY-PREG open cohort provides a dynamic characterisation of menstrual cycle patterns
473   and reproductive outcomes through a two-way longitudinal study. The demographic and general
474   population characteristics of the EARLY-PREG open cohort at present are detailed in Table 1.
475
In Table 2, we present the total number of cycles contributed by participants in the NCG and TCG.

Menstrual Cycle Description and Outcomes

We provide an overview of the participants' menstrual cycle characteristics (Table 3). A total of
405 menstrual cycles have been documented to date, classified as either non-conception (n =
353) or conception cycles (n = 52). Among the conception cycles, 35 resulted in full-term
pregnancies, whereas 17 ended in early pregnancy loss (EPL), which is defined as a miscarriage
until 12 6/7 weeks (American College of Obstetricians and Gynaecologists' Committee on
Practice Bulletins-Gynaecology, 2018).

Menstrual cycles were classified based on whether ovulation took place or not as ovulatory or
anovulatory respectively. Moreover, we included a group of uncharacterised cycles in the process
of classification at the time of submitting this study. Table 4 summarises the distribution of these
cycle types and their corresponding outcome classifications.

Biorepository and sample collection performance
489
490   A total of 405 menstrual cycles have been monitored in the EARLY-PREG cohort biorepository
491   so far, which includes 6,406 CVF samples, 5,120 urine samples, 1,467 saliva samples, 928 blood
492   samples, and 293 brushing samples collected throughout the menstrual cycles. Additionally, 17
493   placenta and umbilical cord blood samples have been obtained from term pregnancies, providing
494   a valuable resource for studying perinatal outcomes.
495

292 complete menstrual cycles were biologically sampled from the monitored cycles: 43 from the
NCG and 249 from the TCG. The NCG samples collected from the EARLY-PREG cohort included
208 blood samples, 832 CVF samples, 876 urine samples, 279 saliva samples, and 26 cervical
brushing samples. The cohort cycles have been further classified into counterfactual and non-
counterfactual groups to facilitate reproductive studies on pregnancy, early pregnancy loss, and
non-conception. Table 5 presents the total number of samples collected from the complete TCG
cycles (excluding those from NCG). Within the TCG, 78 cycles were classified as counterfactual,
and 171 were classified as non-counterfactual.

Biospecimen Collection by Cycle Day and Type

The collection of biospecimens has been categorised by cycle day and type so far, as shown in
Figure 5. The timeframes enabled the evaluation of samples of non-conception and conception
cycles (pregnancy and early pregnancy loss). We highlight the presence of samples collected
during the first two weeks after conception in this longitudinal cohort study.

Biospecimen Collection Performance

We have evaluated so far the performance of the sample collection by comparing the number of
expected samples to the actual samples obtained during the specified windows of interest. The
efficiency of sample collection is determined by calculating the percentage of completeness within
the windows via Formula (1), and we adjusted the CVF and urine according to Formula (2).

514
$$Performance(\%) = \left(\frac{samples\ collected\ in\ 14\ days}{expected\ samples\ in\ 14\ days}\right) \times 100 \qquad (1)$$

515
$$Performance(\%) = \left(\frac{samples\ collected\ in\ cycle\ length}{expected\ samples\ in\ cycle\ length}\right) \times 100 \qquad (2)$$

516
517
Overall compliance with sample collection during defined windows of interest has been high for
most biospecimens. For CVF, 3,956 out of 4,380 expected samples were collected (90.3%) in the
window from day 0 to 14, and 96.15% were collected in the window adjusted for each patient's
luteal phase length; for urine samples, 3,880 out of 4,380 samples were collected (88.6%) during
the period from days 0 to 14 across study cycles, and 94.29% were collected in the window
adjusted for each patient's luteal phase length. In contrast, compliance was lower for saliva
(collected in wave three and, in some cases, in wave two), with 89.22% in the window adjusted
for each patient's luteal phase length (2). For blood, 1,499 of the 3,600 expected samples were
collected (41.6%) across seven scheduled collections from day 0 to 10 of the window.
527
Throughout the study, a total of 287 out of 462 brushing samples were collected from TCG and
NCG. Brushing was expected at least once per participant, depending on the study aim and
reproductive outcome. During the pregnancy monitoring stage of TCG, 72 out of 105 expected
brushings were collected, resulting in a compliance rate of 68.6%. Among conceptions and EPL,

brushing was expected once or twice (±14 and ±21 days post-ovulation), depending on
gestational progression. Of the 347 expected samples, 215 were obtained, yielding a compliance
of 62.0%.
535
536 **Strengths and limitations**
537
● To our knowledge, the EARLY-PREG cohort is the first study design aiming to research
embryo–mother molecular exchange with a preconception, longitudinal, bidirectional, and
counterfactual approach. This unique strategy allows each participant to serve as their
own control to compare local and systemic effects of the presence or absence of a
naturally conceived embryo, minimising interindividual variability during ultra-early
pregnancy.
● A key strength of this study is its prospective open design, which allows follow-up across
participants for one or more menstrual cycles, providing detailed data across critical
reproductive phases, especially the first two weeks after conception.
● We established a comprehensive multisample biobank including CVF, urine, blood, saliva
and cervical brushings samples, as well as placenta and umbilical cord blood to support
future research in human reproduction.
● In the EARLY-PREG cohort, biological samples were collected exclusively from women.
Like other preconception and pregnancy cohorts, our data on male partners are limited to
information from participating women or a short baseline survey.
● Another limitation is the lack of prior clinical records for the participants. During the
recruitment and baseline surveys, the participants self-reported their medical conditions
and family medical history; however, this information was not verified against existing
medical records.
● Fertilisation events may have taken place without successful implantation, with beta-hCG
testing not detecting these cases. Advances in proteomic profiling in CVF from our
biorepository could allow the identification of markers that recognise these events.
● Like many voluntary longitudinal studies, the cohort is susceptible to selective recruitment,
which, combined with geographical constraints, may limit the representativeness of the
findings for broader populations.
563
564 **Future plans**
565
The EARLY-PREG cohort biorepository has reached a sufficient size and number of biological
samples to begin characterising the longitudinal proteomes of the conception and non-conception
cycles. The extensive collection of women's and maternal biospecimens opens the possibility for
future advances in the study of longitudinal changes in the proteome throughout key stages of
female human reproduction. Additionally, biological samples have been collected from full-term
pregnancies, providing a valuable resource for further research on perinatal outcomes.
572
We project to identify local and systemic maternal responses associated with the embryo–mother
molecular dialogue in the early stages of pregnancy. To this end, we will analyse biological
samples from the EARLY-PREG cohort using a proteomics approach, following the proposed

design and workflow of Figure 6, in which consecutive days during the early pregnancy stage are
compared between participants who achieved pregnancy and their respective previous non-
conception counterfactual cycles.
579
In a companion study (Hernandez *et al.,* 2025), we validated a first data-independent acquisition
parallel accumulation–serial fragmentation (dia-PASEF) method for CVF MS-based proteomics
analysis in this biofluid. Based on this work, we will characterise the molecular communication
between the embryo and the mother. This will be complemented by subsequently analysing other
biospecimens such as blood and urine. Our study is intended to cover the period from ovulation
to post-embryo implantation (day 0 to 14). The primary objective of this stage is to identify the
proteome signature of conception by comparing the CVF proteome of participants who
successfully conceived with their respective counterfactual non-conception cycles, while also
quantifying associated biological processes and potential biomarkers. The biospecimens
collected will also enable us to characterise additional key periods of human reproduction,
including the fertile window (-5 to 0 days) (Wilcox *et al.*, 1995), the periovulatory window (-3 to 3
days), and the implantation window (7 to 10 days), synchronised according to the day of ovulation
or embryo implantation (see figure 4).
593
Finally, a new recruitment wave of the EARLY-PREG study is set to begin exploring maternal
immunoregulation and the microbiome during the ultra-early stages of pregnancy. This new wave
will involve a multi-omic approach, incorporating advanced techniques such as flow cytometry,
proteomic, metaproteomic, and metagenomic analyses. We will collect cervical fluid, endometrial
biopsy, and stool samples, in addition to baseline samples, including CVF, urine, blood, saliva,
and cervical brushing. This design facilitates comparisons following the proposed counterfactual
framework. The results obtained may contribute to future research on maternal health and fertility
and represent an important step towards future studies of biomarkers of ultra-early pregnancy.
602
603   **Collaboration**
604
605   The datasets generated and/or analysed during the current study are not publicly available
606   because of the sensitivity of the participant material. Data requests can be sent to the
607   corresponding author.
608
609   **Contributors**
610
E.S.K. conceived the original study using a two-way open longitudinal design. C.V. and J.S.
contributed to the implementation of all three recruitment waves. M.H., E.C and B.A. contributed
to the implementation and maintenance of the biobank. V.L., G.N., and C.V.   contributed with
database construction and data analysis. D.A., V.L., G.N., and B.A. drafted the working
manuscript, and E.S.K., C.V., I.F-M., and G.N. reviewed and commented on drafts. All the authors
approved the final manuscript. E.S.K. is the guarantor of the study, accepts full responsibility for
the research, has full access to the data, and controls the decision to publish.
618
619   **Funding**

620
The EARLY-PREG preconception open cohort has been supported by multiple research grants
awarded by the FISAR Foundation (www.fisarchile.org). The pilot study and the first wave of
recruitment were supported by grants #MEL109112011 and #MEL109112011R4 awarded to
E.S.K., C.V. and J.F.S. The second wave of recruitment was supported by supplemental grants
#MEL109112011R5 and #MEL131032017R1 awarded to E.S.K. The third wave was supported
by grant #MEL205062018 awarded to E.S.K. and M.H. Current funding for the design of the fourth
recruitment wave and MS research on maternal CVF is supported by grant No. REH042024-01
awarded to M.H., G.N., and E.S.K.
629

Acknowledgments

We wish to express our deepest gratitude to all the participants and couples who took part in the
complex and demanding EARLY-PREG open cohort. We would also like to thank all midwives,
obstetricians, nurses, other medical staff, laboratory and research personnel, and administrative
staff for the management of participants and their pivotal role in data collection. We thank
Estefania Nova-Lamperti for her support in figure design, and Ivo Fierro-Monti for advice and
revision of language.

Conflict of interest statement

As a senior scientist, E.S.K. has served as an honorary research advisor and/or reviewer on
research applications for the FISAR Foundation since 2015. No other conflicts of interest are
reported.

Data availability statement

The data are available upon reasonable request. All data relevant to the study are included in the
manuscript.

References

Aghaeepour N, Lehallier B, Baca Q, Ganio EA, Wong RJ, Ghaemi MS, Culos A, El-Sayed YY,

Blumenfeld YJ, Druzin ML, *et al.* A proteomic clock of human pregnancy. *Am J Obstet*

Gynecol 2018;**218**:347.e1–e347.e14. Am J Obstet Gynecol.

American College of Obstetricians and Gynecologists' Committee on Practice Bulletins-

Gynecology. ACOG Practice Bulletin no. 200: Early pregnancy loss. *Obstet Gynecol*

2018;**132**:e197–e207.

Bader JM, Albrecht V, Mann M. MS-based proteomics of body fluids: The end of the beginning.

Mol Cell Proteomics 2023;**22**:100577. Elsevier BV.

Barnea ER. Insight into early pregnancy events: the emerging role of the embryo: Embryo

maternal dialogue. *Am J Reprod Immunol* 2004;**51**:319–322. Wiley.

Barnea ER. Applying embryo-derived immune tolerance to the treatment of immune disorders.

Ann N Y Acad Sci 2007;**1110**:602–618. Wiley.

Barnea ER, Kirk D, Paidas MJ. Preimplantation factor (PIF) promoting role in embryo

implantation: increases endometrial integrin-α2β3, amphiregulin and epiregulin while

reducing betacellulin expression via MAPK in decidua. *Reprod Biol Endocrinol* 2012;**10**:50.

Springer Nature.

Barnea ER, Lahijani KI, Roussev R, Barnea JD, Coulam CB. Use of lymphocyte platelet binding

assay for detecting a preimplantation factor: a quantitative assay. *Am J Reprod Immunol*

1994;**32**:133–138. Wiley.

Barnea ER, Lubman DM, Liu Y-H, Absalon-Medina V, Hayrabedyan S, Todorova K, Gilbert RO,

Guingab J, Barder TJ. Insight into PreImplantation Factor (PIF*) mechanism for embryo

protection and development: target oxidative stress and protein misfolding (PDI and HSP)

through essential RIKP [corrected] binding site. *PLoS One* 2014;**9**:e100263. Public Library

of Science (PLoS).

Benagiano G, Mancuso S, Gianaroli L, Di Renzo GC. Gestation vs pregnancy. *Am J Obstet*

Gynecol 2023a;**229**:91–92. Elsevier BV.

Benagiano G, Mancuso S, Guo S-W, Di Renzo GC. Events leading to the establishment of

pregnancy and placental formation: The need to fine-tune the nomenclature on pregnancy

and gestation. *Int J Mol Sci* 2023b;**24**:15420. MDPI AG.

Burnett LA, Nowak RA. Exosomes mediate embryo and maternal interactions at implantation and

during pregnancy. *Front Biosci (Schol Ed)* 2016;**8**:79–96. IMR Press.

Cha J, Sun X, Dey SK. Mechanisms of implantation: strategies for successful pregnancy. *Nat*

Med 2012;**18**:1754–1767. Springer Science and Business Media LLC.

Cox J, Mann M. Quantitative, high-resolution proteomics for data-driven systems biology. *Annu*

Rev Biochem 2011;**80**:273–299. Annual Reviews.

Das M, Kale V. Extracellular vesicles: Mediators of embryo-maternal crosstalk during pregnancy

and a new weapon to fight against infertility. *Eur J Cell Biol* 2020;**99**:151125. Elsevier BV.

Dimova T, Alexandrova M, Vangelov I, You Y, Mor G. The modeling of human implantation and

early placentation: achievements and perspectives. *Hum Reprod Update* 2024;dmae033.

Oxford University Press (OUP).

Eichler H-G, Bloechl-Daum B, Bauer P, Bretz F, Brown J, Hampson LV, Honig P, Krams M,

Leufkens H, Lim R, *et al.* 'threshold-crossing': A useful way to establish the counterfactual in

clinical trials? *Clin Pharmacol Ther* 2016;**100**:699–712. Wiley.

Fazeli A. Maternal communication with gametes and embryo: a personal opinion: Maternal

communication with gametes and embryo. *Reprod Domest Anim* 2011;**46 Suppl 2**:75–78.

Wiley.

Fernandez-Hermida Y, Grande G, Menarguez M, Astorri AL, Azagra R. Proteomic Markers in

Cervical Mucus. *Protein Pept Lett.* 2018;**25**:463-471.

Geyer PE, Holdt LM, Teupser D, Mann M. Revisiting biomarker discovery by plasma proteomics.

Mol Syst Biol 2017;**13**:942. Mol Syst Biol.

Godbert S, Miro F, Shreeves C, Gnoth C, Johnson S. Comparison between the different methods

developed for determining the onset of the LH surge in urine during the human menstrual

cycle. *Arch Gynecol Obstet* 2015;**292**:1153–1161. Springer Science and Business Media

LLC.

Hedman AM, Lundholm C, Andolf E, Pershagen G, Fall T, Almqvist C. Longitudinal plasma

inflammatory proteome profiling during pregnancy in the Born into Life study. *Sci Rep*

2020;**10**:17819. Springer Science and Business Media LLC.

Hill JA. Maternal-embryonic cross-talk. *Ann N Y Acad Sci* 2001;**943**:17–25. Wiley.

Hernandez M, Saldivia P, Latapiat V, Antilef B, -nourdin G, Castro F, Vargas C, Koch ES.

High-throughput longitudinal proteomics of cervicovaginal fluid during consecutive days of
women's menstrual cycles: a new robust, sensitive, and efficient method. medRxiv
2025.05.19.25327800; doi: https://doi.org/10.1101/2025.05.19.25327800

Kaminski V de L, Ellwanger JH, Chies JAB. Extracellular vesicles in host-pathogen interactions
and immune regulation - exosomes as emerging actors in the immunological theater of
pregnancy. *Heliyon* 2019;**5**:e02355. Elsevier BV.

Lane M, Robker RL, Robertson SA. Parenting from before conception. *Science* 2014;**345**:756–
760. American Association for the Advancement of Science (AAAS).

Lédée N, Dubanchet S, Oger P, Meynant C, Lombroso R, Ville Y, Chaouat G. Uterine receptivity
and cytokines: new concepts and new applications. *Gynecol Obstet Invest* 2007;**64**:138–143.
S. Karger AG.

Lynch CD, Jackson LW, Buck Louis GM. Estimation of the day-specific probabilities of conception:
current state of the knowledge and the relevance for epidemiological research. *Paediatr*
Perinat Epidemiol 2006;**20 Suppl 1**:3–12. Wiley.

Minsal, "Guía Perinatal 2015" Minsal, accessed April 03, 2025,
http://www.repositoriodigital.minsal.cl/bitstream/handle/2015/436/GUIA-PERINATAL_2015-
PARA-PUBLICAR.pdf.

Morton H. Early pregnancy factor: an extracellular chaperonin 10 homologue. *Immunol Cell Biol*
1998;**76**:483–496. Immunol Cell Biol.

Morton H, Tinneberg HR, Rolfe B, Wolf M, Mettler L. Rosette inhibition test: a multicentre
investigation of early pregnancy factor in humans. *J Reprod Immunol* 1982;**4**:251–261.
Elsevier BV.

Muter J, Lynch VJ, McCoy RC, Brosens JJ. Human embryo implantation. *Development* [Internet]
2023;**150.**:

Nahhas F, Barnea E. Human embryonic origin early pregnancy factor before and after
implantation. *Am J Reprod Immunol* 1990;**22**:105–108. Wiley.

O'Neill C. Embryo-derived platelet activating factor. *Reprod Fertil Dev* 1992;**4**:283–288. CSIRO

Publishing.

O'Neill C. The role of paf in embryo physiology. *Hum Reprod Update* 2005;**11**:215–228. Oxford

University Press (OUP).

Romero R, Erez O, Maymon E, Chaemsaithong P, Xu Z, Pacora P, Chaiworapongsa T, Done B,

Hassan SS, Tarca AL. The maternal plasma proteome changes as a function of gestational

age in normal pregnancy: a longitudinal study. *Am J Obstet Gynecol* 2017;**217**:67.e1–

e67.e21.

Santos ED, Moindjie H, Sérazin V, Arnould L, Rodriguez Y, Fathallah K, Barnea ER, Vialard F,

Dieudonné M-N. Preimplantation factor modulates trophoblastic invasion throughout the

decidualization of human endometrial stromal cells. *Reprod Biol Endocrinol* 2021;**19**:96.

Springer Science and Business Media LLC.

Shibata S, Endo S, Nagai LAE, H Kobayashi E, Oike A, Kobayashi N, Kitamura A, Hori T,

Nashimoto Y, Nakato R, *et al.* Modeling embryo-endometrial interface recapitulating human

embryo implantation. *Sci Adv* 2024;**10**:eadi4819. American Association for the Advancement

of Science (AAAS).

Simon C, Greening DW, Bolumar D, Balaguer N, Salamonsen LA, Vilella F. Extracellular vesicles

in human reproduction in health and disease. *Endocr Rev* 2018;**39**:292–332. Endocr Rev.

Singh M, Chaudhry P, Asselin E. Bridging endometrial receptivity and implantation: network of

hormones, cytokines, and growth factors. *J Endocrinol* 2011;**210**:5–14. Bioscientifica.

Somerset DA, Zheng Y, Kilby MD, Sansom DM, Drayson MT. Normal human pregnancy is

associated with an elevation in the immune suppressive CD25+ CD4+ regulatory T-cell

subset. *Immunology* 2004;**112**:38–43. Wiley.

Wilcox AJ, Weinberg CR, Baird DD. Timing of sexual intercourse in relation to ovulation. Effects

on the probability of conception, survival of the pregnancy, and sex of the baby. *N Engl J*

Med 1995;**333**:1517–1521.

Yohannes E, Ippolito DL, Damicis JR, Dornisch EM, Leonard KM, Napolitano PG, Ieronimakis N.

Longitudinal proteomic analysis of plasma across healthy pregnancies reveals indicators of

gestational age. *Int J Mol Sci* 2022;**23**:7076. MDPI AG.

Zegels G, Van Raemdonck GA, Tjalma WA, Van Ostade XW. Use of cervicovaginal fluid for the

identification of biomarkers for pathologies of the female genital tract. *Proteome Sci*.

2010;8:63.

Zhang Y, Wang Q, Wang H, Duan E. Uterine fluid in pregnancy: A biological and clinical outlook.

Trends Mol Med 2017;**23**:604–614.

FIGURE LEGENDS

Figure 1. EARLY-PREG cohort design.

The figure represents our two main study groups: Participants trying to conceive (TCG) and a

negative control group (NCG), and illustrates the endometrium in three distinct scenarios —

conception cycle when pregnancy occurs, non-conception cycle when pregnancy does not occur,

and control cycle without pregnancy due to abstinence and/or sterilisation— along with the

anticipated outcomes.

Figure 2. Flow chart of the EARLY-PREG open cohort design.

Figure 3. EARLY-PREG cohort workflow scheme.

A. Systematic collection of biological samples (CVF, saliva, blood, cervical brushing, and urine)

from participants actively trying to conceive and participants not trying to conceive. In addition,

cervical brushing is performed on day 21 post-ovulation for each participant with a clinically

confirmed pregnancy. Cycle days are expressed in distance from ovulation day (day 0). B. For

participants who achieve pregnancy, additional samples, such as umbilical cord blood and

placenta, are obtained at delivery.

Figure 4. Synchronisation methods based on ovulation and the implantation process using

urine samples.

The figure illustrates two types of synchronisations: one based on luteinising hormone (LH)

concentration for ovulation assessment, and the other on beta-hCG concentration for embryo

implantation. The red, blue, and green lines represent three LH concentration profiles from cycles

of the same participant. Panels A, B and C show synchronisation based on ovulation day and LH

concentration for two consecutive non-conception cycles and a third conception cycle in the

participant P170 of the cohort. In panel A, the cycles are non-synchronised. In panel B, the cycles

are synchronised using the LH surge strategy proposed by Godbert et al. (2015). In panel C, the

cycles were synchronised through the LH peak concentration. Panel D presents synchronisation

based on beta-hCG presence in counterfactual cycles of three participants, P53, P65, and P139

of the EARLY-PREG open cohort. The cells represent a specific day (D) of the menstrual cycle

for each participant, aligned according to the beta-hCG synchronisation approach. The colours in

the table indicate different phases of the cycle: pre-ovulation window (orange), ovulation day

(yellow), pre-implantation window (blue) and implantation/post-implantation window (green). This

alignment enables a standardised comparison of parallel time windows across counterfactual

cycles in the same individual.

Figure 5. Total sample count per day across cycles in complete cycles.

The x-axis represents the days relative to the cycle, standardised according to the day of

ovulation, whereas the y-axis indicates the total number of collected samples. A. Total sample

count for EPL, pregnancy, and non-conception cycles. B. Counts of samples per day in total

cycles. Sample types are colour-coded: CVF (green), blood (red), urine (magenta) saliva (light

blue), and brushing (lime green). EPL, early pregnancy loss; CVF, cervicovaginal fluid.

Figure 6. Proposed designs for analytic comparisons across the cycles and samples of

the EARLY-PREG cohort.

Panel A illustrates a cross-sectional comparison approach, where each day is compared with its

equivalent in both conception and non-conception cycles, following synchronisation (based on LH

surge or beta-hCG). Panels B and C present longitudinal comparison approaches. In panel B,

days are aligned according to the day of ovulation/fertilisation, synchronised using the LH surge,

in both conception and non-conception cycles. Panel C uses the same approach but aligns days

based on implantation. This method employs beta-hCG as an implantation marker, which serves

as the reference point for synchronisation under this standard. All comparisons presented are

based on a counterfactual model of the EARLY-PREG open cohort.

WHAT DOES THIS MEAN FOR PATIENTS?

Previous studies have shown that a successful pregnancy relies on an exchange of signals between the embryo and the mother. This complex communication begins just after the sperm meets the egg—before the embryo attaches to the uterus—during a stage called the preimplantation period. Although it plays a critical role in preparing the maternal body for pregnancy, the mechanisms behind this communication are still not fully understood.

The unique "dialogue" between the embryo and the mother is a two-way exchange known as embryo–maternal crosstalk. Research has suggested that this interaction, mediated by molecules in the uterine fluid, helps the embryo implant properly and modulates the maternal immune system to ensure acceptance of the embryo.

To date, most of what we know about this process comes from animal studies and laboratory experiments, which may not accurately reflect what happens in spontaneous human pregnancies. To better understand this embryo–maternal crosstalk, we designed the EARLY-PREG preconception open cohort. This study follows healthy women who are trying to become pregnant, following them from before conception through the first two weeks of a natural conception and continuing into pregnancy and childbirth. It includes the daily collection of maternal body fluid samples —such as saliva, urine, blood, and cervicovaginal fluid— during key phases of the menstrual cycle. The samples are processed, preserved and stored in a biorepository for research with omic techniques.

In a companion study (Hernandez et al., 2025), we validated a first data-independent acquisition parallel accumulation–serial fragmentation (dia-PASEF) method for CVF MS-based proteomics analysis in these biofluids. EARLY-PREG aims to explain how pregnancy begins, and why some pregnancies succeed while others do not. This knowledge may deepen our understanding of how life begins, and reveal key biological clues to improve fertility care, assisted reproduction and support early pregnancy health.

Table 1. Demographic and reproductive characteristics of the enrolled participants in the EARLY-PREG cohort.

			Negative Controls (NCG)	
	Total	**Trying to Conceive (TCG)**	**Abstinence** [a]	**Sterilised** [b]
Participants, N (%)	223 (100)	154 (69)	62 (28)	7 (3)
Age, mean [SD]	29.21 [4.85]	30.30 [4.36]	25.95 [4,35]	35.29 [2.25]
between 18 and 25, N (%)	52 (23.32)	21 (13.64)	31 (50.00)	0
between 26 and 30, N (%)	82 (36.77)	59 (38.31)	22 (35.48)	0
between 31 and 35, N (%)	71 (31.84)	60 (38.96)	9 (14.52)	3 (42.86)
between 36 and 40, N (%)	18 (8.07)	14 (9.09)	0 (0)	4 (57.14)
Age at menarche, mean [SD]	12.66 [1.56]	12.68 [1.53]	12.41 [1,64]	14.29 [0.88]
BMI, mean [SD]	24.80 [2,91]	24.88 [2.9]	24.47 [2.89]	24.8 [3.47]
Gynaecological history				
Gravidity, N (%)				
0	114 (51.12)	67 (43.51)	47 (75.81)	0 (0)
1	69 (30.94)	61 (39.61)	8 (12.9)	0 (0)
2	30 (13.45)	20 (12.99)	6 (9.68)	4 (57.14)
>3	10 (4.49)	6 (3.9)	1 (1.61)	3 (42.86)
Parity, N (%)				
Nullipara	134 (60.09)	86 (55.84)	48 (77.42)	0 (0)
1	69 (30.94)	59 (38.31)	10 (16.13)	0 (0)
2	17 (7.62)	8 (5.19)	4 (6.45)	5 (71.43)
>3	3 (1.35)	1 (0.65)	0 (0)	2 (28.53)
Miscarriage, N (%)				
0	319 (78.96)	246 (75.46)	58 (93.55)	6 (85.71)
1	65 (16.09)	63 (19.33)	2 (3.23)	1 (14.29)
2	19 (4.7)	17 (5.21)	1 (1.61)	0 (0)
>3	1 (0.25)	0 (0)	1 (1.61)	0 (0)
Educational level				
Secondary school, N (%)	24 (10.76)	21 (13.64)	2 (3.23)	1 (14.29)

Technical education, N (%)	64 (28.7)	46 (29.87)	15 (24.19)	3 (42.86)
Incomplete university level, N (%)	36 (16.14)	11 (7.14)	23 (37.10)	2 (28.57)
Complete university level, N (%)	93 (41.7)	73 (47.40)	19 (30.65)	1 (14.29)
Postgraduate, N (%)	6 (2.69)	3 (1.95)	3 (4.84)	0 (0)

(%) refers to the proportion of women/N within the sample, where N is the number of participants in the category.

BMI, body mass index.

[a] Refers to women without sexual activity who contributed menstrual cycle data to the EARLY-PREG cohort.

[b] Refers to women who underwent tubal sterilisation. Sterilised participant cycles can be with or without sexual activity.

Table 2. Number of cycles contributed by participants per group.

	Volunteers			Cycles	
	Trying to Conceive (TCG)	**Negative Controls (NCG)**		**Non conception**	**Conception**
		Abstinence	**Sterilised**		
1 cycle, N (%)	64 (51.61)	53 (42.74)	7 (5.65)	102	22
2 cycles, N (%)	47 (82.46)	9 (17.54)	0 (0)	95	17
3 cycles, N (%)	23 (100)	0 (0)	0 (0)	61	8
4 cycles, N (%)	6 (100)	0 (0)	0 (0)	22	2
5 cycles, N (%)	9 (100)	0 (0)	0 (0)	41	4
6 cycles, N (%)	5 (100)	0 (0)	0 (0)	30	0
Total, N	154	62	7	351	53

N represents the number of participants who contributed between 1 and 6 cycles in their respective categories.

(%) represents the proportion of contributors per group/individuals per cycle category.

Table 3. Menstrual cycle characteristics according to outcome in the EARLY-PREG cohort.

	Total	Non-conception cycles [a]	Conception cycles	
			Pregnancy	EPL
Total cycles, n	404	351	35	18
Complete cycles, n (%) [b]	293 (72.35)	240 (68.27)	35 (100)	18 (100)
Total cycle length, mean days [SD] [c]	-	28.69 [3.75]	268.26 [11.27] [d]	40.61 [10.36] [f]
Follicular phase, mean days [SD]	15.72 [3.25]	14.66 [3.23]	15.83 [3.57]	15.10 [3.29]
Luteal phase, mean days [SD] [e]	-	13.98 [2.67]	250.74 [11.97] [e]	24.61 [9.53] [g]
Menstruation, mean days [SD]	4.01 [1.37]	4.02 [1.41]	4.0 [1.16]	3.90 [1.29]

N refers to the number of elements per category.

EPL, early pregnancy loss.

[a]Non-conception cycles include NCG cycles.

[b]Complete cycles were defined as those involving longitudinal monitoring and sample collection from the first day of menstruation until the beginning of the next cycle (non-conception cycles) or until miscarriage or full-term pregnancy (conception cycles), with minimal data loss during the follow-up stage.

[c]The cycle length and duration of each phase (follicular, luteal, and menstrual) were calculated using complete cycles and are presented as the mean days and corresponding standard deviations.

[d]The length of pregnancy is defined as the number of days from the beginning of the cycle to delivery.

[e]During pregnancy, the length of the luteal phase is defined as the number of days from the day after ovulation to delivery.

[f]The length of EPL is defined as the period from the beginning of the cycle to the first day of bleeding after a positive beta-hCG test.

[g]The length of the luteal phase is defined as the period from the day after ovulation to the first day of bleeding after a positive beta-hCG test.

Table 4. Quantification of menstrual cycles according to the outcomes and occurrence of ovulation in the EARLY-PREG cohort.

Cycle type	Non-conception [a], n (%)	Conception cycles	
		Pregnancy	EPL
Ovulatory [b]	95	35	17
Anovulatory	15	-	-
Uncharacterised [c]	131	-	-

EPL, early pregnancy loss.

[a]Non-conception cycles include NCG cycles.

[b]Ovulation was assessed by ecography and LH measurement (fertility monitor or test strips and surge calculation; Godbert et al., 2015).

[c]Samples without LH measurement or ultrasound, and ovulation confirmation based on progesterone measurement

Table 5. Classification of complete cycles of the TCG in the EARLY-PREG cohort. EPL, early pregnancy loss; CVF, cervicovaginal fluid.

	Total	Counterfactual			Non-Counterfactual		
		Conception cycle		Non conception cycle	Conception cycle		Non conception cycle
		Pregnancy	EPL		Pregnancy	EPL	
Cycles							
Complete	250	20	9	36	15	8	162
Samples							
CVF	5,503	416	178	708	272	142	3,787
Blood	1,449	102	63	178	98	73	935
Urine	5,854	444	182	775	278	134	4,041
Saliva	2,020	129	43	865	95	23	865
Cervical Brushing	231	38	13	28	23	7	122

Figure 1. EARLY-PREG cohort design.The figure represents our two main study groups: Participants trying to conceive (TCG) and a negative control group (NCG), and illustrates the endometrium in three distinct scenarios —conception cycle when pregnancy occurs, non-conception cycle when pregnancy does not occur, and control cycle without pregnancy due to abstinence and/or sterilisation— along with the anticipated outcomes.

284x177mm (300 x 300 DPI)

Figure 2. Flow chart of the EARLY-PREG open cohort design.

193x150mm (300 x 300 DPI)

Figure 3. EARLY-PREG cohort workflow scheme. A. Systematic collection of biological samples (CVF, saliva, blood, cervical brushing, and urine) from participants actively trying to conceive and participants not trying to conceive. In addition, cervical brushing is performed on day 21 post-ovulation for each participant with a clinically confirmed pregnancy. Cycle days are expressed in distance from ovulation day (day 0). B. For participants who achieve pregnancy, additional samples, such as umbilical cord blood and placenta, are obtained at delivery.

334x209mm (300 x 300 DPI)

Figure 4. Synchronisation methods based on ovulation and the implantation process using urine samples. The figure illustrates two types of synchronisations: one based on luteinising hormone (LH) concentration for ovulation assessment, and the other on beta-hCG concentration for embryo implantation. The red, blue, and green lines represent three LH concentration profiles from cycles of the same participant. Panels A, B and C show synchronisation based on ovulation day and LH concentration for two consecutive non-conception cycles and a third conception cycle in the participant P170 of the cohort. In panel A, the cycles are non-synchronised. In panel B, the cycles are synchronised using the LH surge strategy proposed by Godbert et al. (2015). In panel C, the cycles were synchronised through the LH peak concentration. Panel D presents synchronisation based on beta-hCG presence in counterfactual cycles of three participants, P53, P65, and P139 of the EARLY-PREG open cohort. The cells represent a specific day (D) of the menstrual cycle for each participant, aligned according to the beta-hCG synchronisation approach. The colours in the table indicate different phases of the cycle: pre-ovulation window (orange), ovulation day (yellow), pre-implantation window (blue) and implantation/post-implantation window (green). This alignment enables a standardised comparison of parallel time windows across counterfactual cycles in the same individual.

344x180mm (300 x 300 DPI)

Figure 5. Total sample count per day across cycles in complete cycles. The x-axis represents the days relative to the cycle, standardised according to the day of ovulation, whereas the y-axis indicates the total number of collected samples. A. Total sample count for EPL, pregnancy, and non-conception cycles. B. Counts of samples per day in total cycles. Sample types are colour-coded: CVF (green), blood (red), urine (magenta) saliva (light blue), and brushing (lime green). EPL, early pregnancy loss; CVF, cervicovaginal fluid.

225x263mm (300 x 300 DPI)

Figure 6. Proposed designs for analytic comparisons across the cycles and samples of the EARLY-PREG cohort. Panel A illustrates a cross-sectional comparison approach, where each day is compared with its equivalent in both conception and non-conception cycles, following synchronisation (based on LH surge or beta-hCG). Panels B and C present longitudinal comparison approaches. In panel B, days are aligned according to the day of ovulation/fertilisation, synchronised using the LH surge, in both conception and non-conception cycles. Panel C uses the same approach but aligns days based on implantation. This method employs beta-hCG as an implantation marker, which serves as the reference point for synchronisation under this standard. All comparisons presented are based on a counterfactual model of the EARLY-PREG open cohort.

254x239mm (300 x 300 DPI)